Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Oncology·MeSH: Prostatic Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
9 drugs in development·1 company·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| docetaxel | PFIZER INC (PFE) |
Phase 3(2)
Unknown(5)
Phase 4(1)
| Drug | Company |
|---|---|
| abiraterone | PFIZER INC (PFE) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Castration Sensitive Prostate Cancer (mCSPC)?
BioSniper tracks 9 drugs in development for Metastatic Castration Sensitive Prostate Cancer (mCSPC) across 1 company.
How many clinical trials target Metastatic Castration Sensitive Prostate Cancer (mCSPC)?
There are 3 clinical trials targeting Metastatic Castration Sensitive Prostate Cancer (mCSPC) tracked by BioSniper.
What is the prevalence of Metastatic Castration Sensitive Prostate Cancer (mCSPC)?
The estimated prevalence of Metastatic Castration Sensitive Prostate Cancer (mCSPC) is approximately 256.0 per 100,000 population.
Deep-dive into Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis